GET DAILY SIGNALSIntegra LifeSciences (IART) Delivers Mixed Q4 Results While Setting 2026 Recovery Path
Key Takeaways
- Fourth-quarter revenue was $434.9 million, down 1.7% year over year and slightly ahead of analyst consensus.
- Adjusted EPS (earnings per share) came in at $0.83, beating estimates but falling 14.4% from the prior-year quarter.
- The company reported a GAAP (generally accepted accounting principles) net loss of $1.7 million, or $0.02 per share.
- Codman Specialty Surgical grew 2.7%, while Tissue Technologies revenue declined 12.8%, driven by weakness in wound reconstruction.
- Full-year 2026 guidance calls for revenue of $1.66 billion to $1.70 billion and adjusted EPS of $2.30 to $2.40.
Earnings Context and Why It Matters
Integra LifeSciences (IART) closed out a difficult 2025 with fourth-quarter results that highlighted both progress and persistent pressure. The medical technology company has been navigating quality remediation efforts, supply constraints, and tariff headwinds, even as demand across much of its surgical portfolio remains solid. For investors, this report matters because it offers a clearer read on whether Integra is moving past its operational challenges, and because management's 2026 guidance sets the bar for a potential recovery. The sharp divergence between its two business segments—one growing and one shrinking—frames the key question heading into the new year. I also checked this using Tickeron’s AI Screener to see how the stock compares to others in the industry.
Reported Results
Integra LifeSciences (IART) reported fourth-quarter 2025 revenue of $434.9 million, a decline of 1.7% on a reported basis and 2.5% on an organic basis compared with the prior-year period. The top line edged past the Zacks Consensus Estimate of roughly $434 million. Adjusted EPS came in at $0.83, exceeding consensus expectations of about $0.79 to $0.80, though the figure was down from $0.97 a year earlier. On a GAAP basis, the company posted a net loss of $1.7 million, or $0.02 per share, compared with a profit of $0.25 per share in the year-ago quarter.
Segment results told a divergent story. Codman Specialty Surgical revenue rose 2.7% to $323.3 million, supported by strength in neurosurgery, instruments, and ENT (ear, nose, and throat) products. Tissue Technologies revenue fell 12.8% to $111.6 million, with wound reconstruction down 21.4% on an organic basis due to remediation work on MediHoney and a tough comparison against a record prior-year quarter for Integra Skin. Private label sales rose 20.1%.
For the full year, revenue was $1.635 billion, up 1.5% on a reported basis, while adjusted EPS was $2.23, down 12.9% from 2024. Adjusted gross margin in the fourth quarter was 61.7%, down 350 basis points year over year, reflecting tariffs, compliance costs, and an unfavorable product mix.
Market Reaction and Investor Sentiment
Shares of Integra LifeSciences (IART) moved modestly higher following the report, rising around 0.4% after the announcement and roughly 3.5% in pre-market trading. The relatively muted reaction reflects a market weighing two opposing signals: a top-line and adjusted-EPS beat against a year-over-year earnings decline, continued margin compression, and a still-weak Tissue Technologies segment. Sentiment remains cautious given that the stock has traded near 52-week lows after a difficult year, and investors appear focused more on the trajectory of 2026 guidance than on the quarter's headline beat.
Forward Outlook and Key Factors to Monitor
Management's guidance is the central reference point for the year ahead. For full-year 2026, Integra expects revenue of $1.66 billion to $1.70 billion, implying reported growth of 1.6% to 4.1%, and adjusted EPS of $2.30 to $2.40. First-quarter 2026 guidance calls for revenue of $375 million to $390 million and adjusted EPS of $0.37 to $0.45.
Several factors will shape whether Integra can meet those targets. Supply reliability and the completion of its quality remediation work remain the primary drivers of performance predictability. Investors should watch for progress on the Braintree manufacturing facility and the planned return of SurgiMend to the market in the fourth quarter of 2026, as well as ongoing EU MDR (European Union Medical Device Regulation) compliance spending.
Margin recovery is another key watch item. Tariffs and compliance costs pressured gross margin throughout 2025, and management's guidance reflects tariff assumptions made before a recent Supreme Court ruling on Section 122 tariffs. Cost management and a rebound in wound reconstruction will be essential to stabilizing profitability.
Finally, free cash flow is expected to improve as heavy infrastructure investments wind down, a development that could support deleveraging. With net debt around $1.6 billion and a leverage ratio near 4.5x, any progress on cash generation will be closely scrutinized.
Using AI Tools in My Research
From what I see, tools like Tickeron’s AI Screener help me quickly compare companies like Integra LifeSciences against peers in the medical technology space. I use it to filter by fundamentals, technical patterns, and industry trends, which gives me a clearer view of relative performance without spending hours on manual analysis. It has become a regular part of how I evaluate earnings reports and sector opportunities.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
Contributor
Sergey Savastiouk, Ph.D. has a degree in Applied Mathematics from Moscow University and has extensive experience as an entrepreneur, investor, manager, and mathematician. His professional expertise is in applied mathematics, mathematical modeling, system and pattern analysis, and software and hardware system integration. He has served as the CEO of several hi-tech start-up companies and nonprofit organizations, which has given him proven capabilities in business strategy for high-tech start-up companies, market assessment, company formation, team building, product development, marketing, and sales. He has published numerous articles in journals and magazines on related fields. As a retail investor, he spent 15 years developing his proprietary trading and quantitative algorithms (now Tickeron’s A.I.), which brought him significant returns in trading the stock market. His current work and goal in founding Tickeron is to bring professional, sophisticated stock market analysis capabilities to retail investors via an easy-to-use interface.
IART in -5.76% downward trend, declining for three consecutive days on October 14, 2026
Moving lower for three straight days is viewed as a bearish sign. Keep an eye on this stock for future declines. Considering data from situations where IART declined for three days, in 233 of 299 cases, the price declined further within the following month. The odds of a continued downward trend are 78%.
Technical Analysis (Indicators)
Bearish Trend Analysis
The Aroon Indicator for IART entered a downward trend on October 12, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
Bullish Trend Analysis
The RSI Oscillator points to a transition from a downward trend to an upward trend -- in cases where IART's RSI Indicator exited the oversold zone, 27 of 38 resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 71%.
The Stochastic Oscillator suggests the stock price trend may be in a reversal from a downward trend to an upward trend. 37 of 60 cases where IART's Stochastic Oscillator exited the oversold zone resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 62%.
The Momentum Indicator moved above the 0 level on October 16, 2026. You may want to consider a long position or call options on IART as a result. In 62 of 94 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are 66%.
The Moving Average Convergence Divergence (MACD) for IART just turned positive on October 20, 2026. Looking at past instances where IART's MACD turned positive, the stock continued to rise in 26 of 43 cases over the following month. The odds of a continued upward trend are 60%.
Following a +4.25% 3-day Advance, the price is estimated to grow further. Considering data from situations where IART advanced for three days, in 181 of 291 cases, the price rose further within the following month. The odds of a continued upward trend are 62%.
IART may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.
Fundamental Analysis (Ratings)
The Tickeron Valuation Rating of 6 (best 1 - 100 worst) indicates that the company is seriously undervalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (0.883) is normal, around the industry mean (2.979). P/E Ratio (-131.556) is within average values for comparable stocks, (2.590). Projected Growth (PEG Ratio) (0.669) is also within normal values, averaging (11.052). Dividend Yield (0.000) settles around the average of (0.009) among similar stocks. P/S Ratio (0.751) is also within normal values, averaging (40.124).
The Tickeron PE Growth Rating for this company is 16 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Seasonality Score of 28 (best 1 - 100 worst) indicates that the company is slightly undervalued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.
The Tickeron Price Growth Rating for this company is 62 (best 1 - 100 worst), indicating steady price growth. IART’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron SMR rating for this company is 91 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. IART’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 95, placing this stock worse than average.
Notable companies
Industry description
Market Cap
High and low price notable news
Volume
Fundamental Analysis Ratings
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
Advertisement
General Information
a manufacturer of medical devices, implants and biomaterials
Industry MedicalNursingServices
Advertisement